Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (451-460 of 610) with videos related to

Pageof 61
Sort By:
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Nature Communications|April 13, 2019
Hybrid longitudinal-transverse phonon polaritonsChristopher R Gubbin, Rodrigo Berte, Michael A Meeker, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2011
Preclinical testing of tandutinib in a transgenic medulloblastoma mouse modelSachiko Ohshima-Hosoyama, Monika A Davare, Suresh I Prajapati, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
Blood|July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Experimental Gerontology|July 28, 2009
Microarray analysis of senescent vascular smooth muscle cells: A link to atherosclerosis and vascular calcificationDominick G A Burton, Peter J Giles, Angela N P Sheerin, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Nature Chemistry|June 29, 2021
Mechanism of molybdate insertion into pterin-based molybdenum cofactorsCorinna Probst, Jing Yang, Joern Krausze, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Pageof 61

Showing results (451-460 of 610) with videos related to

Sort By:
Pageof 61
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Nature Communications|April 13, 2019
Hybrid longitudinal-transverse phonon polaritonsChristopher R Gubbin, Rodrigo Berte, Michael A Meeker, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2011
Preclinical testing of tandutinib in a transgenic medulloblastoma mouse modelSachiko Ohshima-Hosoyama, Monika A Davare, Suresh I Prajapati, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
Blood|July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Cancer|March 26, 2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaFrancis J Giles, Martin S Tallman, Guillermo Garcia-Manero, et al.
Experimental Gerontology|July 28, 2009
Microarray analysis of senescent vascular smooth muscle cells: A link to atherosclerosis and vascular calcificationDominick G A Burton, Peter J Giles, Angela N P Sheerin, et al.
Leukemia Research|March 21, 2006
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's diseaseMaher Albitar, Julie M Vose, Marcella M Johnson, et al.
Nature Chemistry|June 29, 2021
Mechanism of molybdate insertion into pterin-based molybdenum cofactorsCorinna Probst, Jing Yang, Joern Krausze, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Pageof 61